PharmaShots | Incisive News in 3 Shots

Subscribe Now

Multiple Myeloma

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Mult...

May 2, 2022

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

October 13, 2021

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

October 13, 2021

SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma

SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma

August 30, 2021

SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma

SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma

August 30, 2021

$BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma$

BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma

August 20, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us